Zai Lab heads into its September-quarter report with a split personality. The global pipeline story has rarely looked stronger, and shares have climbed nearly 24% since the last update while the S&P 500 went nowhere. Yet the commercial business in China is still shrinking from a year ago, the company has quietly walked away from a dated profitability target, and the cash pile keeps getting smaller. This report will show whether last quarter's sequential rebound was the start of a durable recovery or a one-quarter bounce that the rally has gotten ahead of.
The Street is looking for revenue of about $108.1 million, which would be a modest step up from the $106.3 million reported last quarter but roughly 7% below the $116.1 million posted in the same period a year ago. A reliable consensus earnings figure is not available, so revenue and spending trends carry more weight than usual. For context, the company lost $0.46 per share last quarter, wider than the $0.33 loss a year earlier. Management has not reinstated full-year revenue guidance since cutting its outlook to at least $460 million in late 2025, leaving its repeated promise of meaningful year-over-year growth in 2027 as the main commercial anchor. A revenue figure only slightly ahead of last quarter fits that narrative: the company is not promising growth now, only that the decline is bottoming.
The key operating question is whether the momentum described on the last call carried through. Management pointed to an 11% sequential jump in product revenue, double-digit sequential volume gains for ViviGuard, and an excellent start for CarXT. Another quarter of sequential growth, particularly in ViviGuard volumes, would validate the inflection story. The complication is that management also warned second-half reported revenue might understate underlying demand because of timing around ViviGuard's shift from intravenous to subcutaneous dosing and national reimbursement listing. That caveat cuts both ways. It gives the company cover if revenue stalls, but investors will want hard volume data showing that demand is genuinely expanding rather than simply being explained away.
The pipeline is where the bull case lives, and this report arrives on the heels of a major scheduled event. The first-line small cell lung cancer combination data for Zosie, the DLL3 antibody-drug conjugate, was slated for ESMO in October, covering roughly 60 patients with eight to nine months of follow-up. Management has expanded its ambitions from a single pivotal program to three registrational efforts by year-end 2026, with a first US filing targeted for 2027 and a potential launch in 2028. Confirmation that those timelines are intact, along with updates on the Amgen combination study, the ZL1503 first-in-human readout and the ZL1311 IND, would reinforce the transformation thesis. Any slippage would be costly given how much of the stock's recent gain likely rests on this story.
The balance sheet is the counterweight. Cash fell from $817 million to $717.5 million over four reports, with the most recent quarter consuming roughly $44 million. Running three registrational programs is expensive, and with profitability now framed as something that arrives naturally over time rather than on a schedule, the pace of burn matters. Clarity on senior leadership following the absence of the president and chief operating officer from the last call would also help.
Sentiment has drifted more bearish, to 51.4% from 43.2% heading into the prior report, even as the stock rallied. Shares sit at $23.58, comfortably above the 200-day moving average near $20.91 but well off the post-earnings high of $27.50, suggesting some enthusiasm has already been tested. Ultimately, the narrative survives if sequential commercial growth continues and pipeline timelines hold without an acceleration in cash burn. A stalled top line paired with rising spending would make the 2027 growth promise look increasingly distant.